Trial reportJournal of hematology & oncology2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab.
Trial report in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03263572 (Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Who cites it
18 citing papers in PubMed.
- High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.Blood research · 2026Review
- Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors.Journal of hematology & oncology · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making.Blood cancer journal · 2026Article
- Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.Cancer · 2026Article
- Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.American journal of hematology · 2026Article
- Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood cancer journal · 2026Article
- Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.Blood cancer journal · 2026Review
- B-Lymphoblastic Leukemia With Isolated Central Nervous System Relapse Mimicking a Vestibular Schwannoma.Clinical case reports · 2026Article
- Relapse patterns focusing on central nervous system involvement after allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia.Bone marrow transplantation · 2026Article
- Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study.Annals of hematology · 2026Article
- A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
- Immune targeting in Ph-negative and Ph-positive B-ALL: improving outcomes and minimizing chemotherapy in adult B-ALL.Hematology. American Society of Hematology. Education Program · 2025Review
- Adapting measurable residual disease evaluation to clinical practice for patients with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.Blood cancer journal · 2025Article
- BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation.Blood cancer journal · 2025Article
- Article
- Efficacy and safety of flumatinib in adults with Ph-positive ALL: a prospective observational study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSeveral studies have suggested that chemotherapy-free regimens consisting of blinatumomab and a BCR::ABL1 tyrosine kinase inhibitor are highly effective in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, the clinical and molecular characteristics that predict for relapse with these chemotherapy-free regimens are largely unknown.
methodsWe conducted a prospective phase II clinical trial of the combination of blinatumomab and ponatinib in 76 patients with newly diagnosed Ph + ALL. Patients received 12-15 doses of intrathecal chemotherapy as central nervous systemic (CNS) prophylaxis. The patterns of relapse and the clinical and molecular predictors of relapse were analyzed.
resultsWith a median follow-up of 29 months, the estimated 3-year event-free survival rate was 78% and the 3-year overall survival rate was 88%. Ten patients (13%) relapsed, with a median time to relapse of 18 months (range, 8-24 months). Six relapses occurred only in extramedullary sites (CNS, n = 5; peritoneum and lymph nodes, n = 1). CD19 expression remained high at relapse in all patients. On univariate analysis, factors associated with an increased risk of relapse were: white blood cell (WBC) ≥ 70 × 10
conclusionsWBC ≥ 70 × 10
trial registrationClinicalTrials.gov (NCT03263572).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.